Guselkumab, an antibody inhibiting IL-23p19, was introduced in one case (14.3%) and ustekinumab, an antagonist of the p40 subunit of IL-12 and IL-23, in the remaining six patients (85.7%) for psoriasis treatment (Table 2). This evidence concerns the gene IL23A and psoriasis.